Hurvitz, the study’s lead author, said the therapy was affecting “many patients with advanced disease.”
Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
A new form of drug drastically improves survival rates of younger women with the most common type of breast cancer, researchers said on Saturday, citing the results of an international clinical trial.An estimated 268,000 new cases of breast cancer are expected to be diagnosed in women in the U.S. in 2019, while the advanced form of the disease is the leading cause of cancer deaths among women aged 20 to 59 .Though advanced breast cancer is less common among younger women, its incidence grew two percent per year in the U.S. between 1978 and 2008 for women aged 20 to 39, according to a previous study.The new trial, which looked at more than 670 cases, included only women who had advanced cancer -- stage four -- for which they had not received prior hormone-blocking therapy.
FOLLOW THIS ARTICLE